Core Insights - OptimizeRx (OPRX) reported a strong first-quarter 2025 performance, with revenues increasing by 11% year-over-year to $21.9 million and adjusted EBITDA reaching $1.5 million, indicating a significant turnaround [1] - The company is increasingly recognized as a strategic commercialization partner, with a reported ROI of over 10:1 and a 25% script lift in six months, highlighting its value in a selective pharma spending environment [2] - More than 80% of OPRX's 2025 revenues are contracted, and the company is transitioning to a subscription-based model, which may enhance margin stability and predictability [3] - OPRX has not experienced significant regulatory pressures or pharma budget volatility, instead benefiting from a client focus on cost-effective digital solutions [4] - In a competitive digital health landscape, OPRX's integration of scalable omnichannel tools and data-driven insights may provide a sustainable advantage if executed effectively [5] Financial Performance - OPRX's shares have surged by 187.9% year-to-date, significantly outperforming the industry growth of 18% [10] - The forward 12-month price-to-sales (P/S) ratio for OPRX is 2.33X, lower than the industry average of 8.86X and its five-year median of 3.57X, indicating potential undervaluation [13] - The Zacks Consensus Estimate for OPRX's 2025 earnings per share suggests a 63.6% improvement from the 2024 level, with estimates ranging from $0.42 to $0.84 for the next year [15][16]

SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2025 after the close of trading on Thursday, July 31, 2025. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived ...

Key Takeaways HIMS surged 90.4% in three months, outpacing peers and driven by gains in online revenue and subscribers. Expansion into Canada and the ZAVA acquisition mark major international growth milestones for HIMS. HIMS projects up to 74% Q2 revenue growth and 63% full-year growth, fueled by demand for GLP-1 therapies.Hims & Hers Health, Inc.’s (HIMS) investors have been experiencing some short-term gains from the stock lately despite its bumpy ride over recent months. The San Francisco, CA-based hea ...

Mobile-health Network Solutions (MNDR) launched an at-the-market (ATM) equity offering to raise up to $300 million to accelerate the growth of its artificial intelligence-powered digital health platform.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS con ...

Virtually-enabled Emergency Department (ED) at Georgian Bay General Hospital has successfully connected over 3,000 patients with MDs,with 97.5% managed virtually and only 1% redirected to the ED.The Ontario program has saved an estimated $1.4 million by diverting 3,065 patients from the ER between June 2022 and December 2024. This is based on an average of $475 per visit, using cost data from Scarborough Health Network and Canadian Institute for Health Information. In the last 3 months across Alberta, Rocke ...

Company Overview - Profusa, Inc. is a commercial stage digital health company based in Berkeley, California, focused on developing tissue-integrated sensors for continuous monitoring of biochemistry [4] - The company aims to provide affordable, long-lasting, injectable biosensors that transmit actionable medical-grade data for personal and medical use [4] Business Combination - Profusa announced the closing of its business combination with NorthView Acquisition Corp. (NVAC), which was approved by NVAC's shareholders on June 9, 2025 [1] - The combined company will operate under the name Profusa, Inc., with common stock expected to begin trading on Nasdaq under the ticker symbol "PFSA" starting July 14, 2025 [1] - A secured convertible promissory note was issued to an institutional investor, raising $9 million to cover transaction costs and support future working capital needs, with a total of up to $20 million available under the convertible note facility [2] Technology and Vision - Profusa's technology platform is designed to continuously monitor and transmit body chemistries to smartphone applications, leveraging advanced data analytics and AI technologies [2] - The company aims to improve health management for chronic diseases such as diabetes, critical limb ischemia (CLI), and peripheral arterial disease (PAD) [2] Leadership and Support - The company is led by a visionary scientific team and an experienced management group, supported by dedicated employees, partners, and investors [2]

Backed by $1 million in funding from the CVS Health Foundation, the pilot initiative offers free, virtual health screenings to support aging with confidence, care, and convenienceHealth checks include assessments for heart health, memory, cognitive function, and mental healthNo travel required — all appointments are virtual and confidentialCommunity Health Workers provide personalized follow-up support and connect patients to local resourcesThe program is now available in New York City, with plans to expand ...

As tariff fears ripple across markets with President Donald Trump sending tariff letters to 12 countries, small-cap resilience is stealing the spotlight. The Russell 2000 index is soaring toward creating new all-time highs. The iShares Russell 2000 ETF IWM, which tracks the Russell 2000 index, is up over 25% from April 8 lows.The recovery is powered in part by a few unlikely stars – Oklo Inc OKLO, NuScale Power Corp SMR and Hims & Hers Health Inc HIMS – each bucking macro gloom with year-to-date gains of 15 ...

Innovative initiative combines QHSLab’s digital platform with on-site behavioral health services to advance timely, effective care. MIAMI, FL, July 08, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. (the “Company”) (OTCQB: USAQ), a digital health company advancing personalized medicine through innovative population health screening and point of care diagnostic tools in primary care, announced today the opening of its first co-branded QHS Behavioral Healthcare Center (QBHC) in Miami. First unveiled in a letter to shar ...

Treatment.com AI completed the acquisition of Rocket Doctor, aligning AI-powered clinical intelligence with a proven virtual care delivery platform.‏Rocket Doctor patient volume grew 112% in Alberta year-over-year, with over 36,000 patients seen in 2024 and physician adoption growing 218%.‏New partnerships launched in California and Canada, including with Central California Alliance for Health, a ~450,000 member managed care plan and Melanoma Canada, a National organization.‏Medical Education Suite deploye ...